Myriad Genetics' Prolaris effective in detecting recurring prostate cancer


Myriad Genetics (MYGN) jumped nearly 11.5% today on news its Prolaris genetic testing method proved effective in predicting which men would see a cancer recurrence following radical prostate surgery (also).

A study published in the Journal of Urology said a test which evaluated more than 5,000 patients across 11 clinical studies showed Prolaris proved more effective in predicting the likelihood that cancer would return than a Gleason Score or PSA test.

The study "represents a great advance in the treatment of prostate cancer," according to the study investigator.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs